Eduovisual
Musculoskeletal
Behcet disease: recognition and management
— Prevalence highest along the ancient Silk Road (Turkey, Iran, Middle East, Central Asia, Japan, Korea); rare but present in US/Europe
— Onset typically ages 20–40; equal sex distribution but more severe in young men and in patients of Middle Eastern/East Asian descent
— Strong association with HLA-B51 (not required for diagnosis; not a screening test)
— Young adult with recurrent painful oral aphthae (≥3 episodes/year) plus any of: recurrent genital ulcers, uveitis, skin lesions, or unexplained venous thrombosis
— Unexplained pulmonary artery aneurysm in a young patient (classic and high-yield)
— Recurrent DVT in a young patient with negative thrombophilia workup
— Sterile pustule at a venipuncture site (pathergy)
— Aseptic meningoencephalitis or brainstem syndrome in a young Mediterranean/Middle Eastern patient
— Autoinflammatory/autoimmune overlap; neutrophilic hyperactivity, Th1/Th17 skew
— Endothelial dysfunction → both thrombosis and aneurysm formation in the same patient
— Most patients first present to primary care, dentistry, dermatology, or ophthalmology with isolated complaints; the diagnosis is clinical and pattern-based over months to years
— No single confirmatory test exists — recognize the syndrome
Board pearl: A young man from Turkey with recurrent oral and genital ulcers, posterior uveitis, and a sterile pustule forming where a nurse drew blood = Behçet until proven otherwise. Pulmonary artery aneurysm in this context is pathognomonic enough to drive empiric immunosuppression even before formal criteria are met.
— Recurrent oral aphthae: painful, round, 1–10 mm, yellow-based, heal in 1–3 weeks without scarring (large ulcers >1 cm may scar); ≥3 episodes/12 months is the criterion threshold
— Genital ulcers: scrotum or vulva more than penile/vaginal; deeper, often scar, less frequent recurrence than oral
— Skin: erythema nodosum–like lesions (lower legs), pseudofolliculitis, acneiform papulopustules, pathergy (pustule 24–48 h after needle prick)
— Bilateral panuveitis with retinal vasculitis is the hallmark
— Hypopyon (sterile pus in anterior chamber) is classic but seen in <20%
— Untreated → blindness within 5 years; vision loss is the most feared outcome
— Venous predominates: recurrent superficial thrombophlebitis and DVT
— Arterial: aneurysms (pulmonary > aorta > peripheral) and occlusions
— Pulmonary artery aneurysm + hemoptysis = "Hughes-Stovin"-like Behçet, very high mortality
— Parenchymal: brainstem/diencephalic lesions, pyramidal signs, behavioral change
— Non-parenchymal: cerebral venous sinus thrombosis, especially in young men
— Ileocecal ulcers mimicking Crohn disease; bleeding, perforation possible
— Non-erosive, non-deforming oligoarthritis of knees/ankles
— Pericarditis, intracardiac thrombus, endomyocardial fibrosis (rare)
Key distinction: Oral aphthae alone are extraordinarily common (canker sores) — only the combination with genital ulcers, eye disease, skin lesions, vascular events, or pathergy should trigger a BD workup. Ask explicitly about genital lesions; patients rarely volunteer them.
Step 3 management: On intake, document ulcer frequency, scarring, and timing — this drives both diagnostic criteria and therapy escalation thresholds.
— Lower extremity tender erythematous nodules (EN-like)
— Trunk/face acneiform/pustular lesions in a post-adolescent adult (acne after age 25 in unusual distribution is a clue)
— Pathergy test: 20-gauge sterile needle prick on the forearm; read at 24–48 h for papule/pustule ≥2 mm — positive in Turkish/Middle Eastern patients (~60%), low yield in Northern European/US patients (~10%) but highly specific when present
— Palpate peripheral pulses; auscultate for bruits over carotids, aorta, femorals
— Asymmetric limb swelling/tenderness → suspect DVT
— Superficial cord-like tender veins → migratory thrombophlebitis
— Look for Budd-Chiari signs: hepatomegaly, ascites, abdominal wall collaterals (suggests hepatic vein thrombosis — poor prognosis)
CCS pearl: In a Behçet patient admitted with hemoptysis, the first orders are CT pulmonary angiogram (looking for aneurysm, not just embolus) and ophthalmology consult — not heparin. Anticoagulating a bleeding PA aneurysm is catastrophic. This trap appears frequently on management questions.
— CBC with differential: mild leukocytosis, anemia of chronic disease possible
— CMP: baseline renal/hepatic function before immunosuppression
— ESR and CRP: often elevated during flares but can be normal — do not exclude BD with normal inflammatory markers
— UA: BD rarely causes glomerulonephritis (unlike ANCA vasculitides); proteinuria/hematuria should prompt rethinking diagnosis or evaluating for AA amyloidosis in long-standing disease
— HIV, RPR, HSV PCR of ulcer if atypical: rule out mimics
— Pregnancy test in women of reproductive age before initiating teratogens
— ANA, ANCA, RF, anti-CCP — typically negative in BD; positive results redirect the differential
— Antiphospholipid panel if thrombosis is present
— HLA-B51 typing is supportive, not diagnostic; sensitivity ~50–80% depending on ethnicity, low PPV in US populations
— Ocular: dilated fundus exam + fluorescein angiography to detect occult retinal vasculitis
— Suspected DVT: lower extremity duplex
— Hemoptysis or chest pain: CT pulmonary angiography (PA aneurysm vs PE)
— Neuro symptoms: MRI brain with contrast and MR venography
— GI symptoms: colonoscopy with ileal intubation; biopsy ulcers
Board pearl: International Criteria for Behçet Disease (ICBD, 2014) — score ≥4: oral aphthae (2), genital aphthae (2), ocular lesions (2), skin lesions (1), neurologic (1), vascular (1), positive pathergy (1). Memorize the "2-2-2" for the big three.
— Slit-lamp: anterior uveitis ± hypopyon
— Dilated fundoscopy: posterior uveitis, retinal vasculitis, vitritis
— Fluorescein angiography: gold standard for detecting subclinical retinal vasculitis (leaking vessels, capillary nonperfusion) — drives systemic immunosuppression even with preserved acuity
— OCT for macular edema monitoring
— CT angiography of chest/abdomen/pelvis if pulmonary or aortic involvement suspected — look for aneurysm + thrombus simultaneously (BD signature)
— Duplex US for venous disease; MR venography for cerebral sinuses, hepatic veins (Budd-Chiari)
— Avoid arteriography when CTA/MRA suffices — vessel puncture can precipitate aneurysm at the access site (vascular pathergy)
— MRI: brainstem/basal ganglia/thalamic T2 hyperintensities (parenchymal neuro-BD)
— MRV: cerebral venous sinus thrombosis
— LP: lymphocytic or neutrophilic pleocytosis, elevated protein, elevated IL-6; exclude infection
— Ileocolonoscopy: large, deep, oval ulcers in the ileocecal region (typically few in number, "punched out") — contrast with Crohn's discontinuous cobblestoning
— Biopsy: nonspecific neutrophilic infiltrate; vasculitis rarely captured
— TTE/TEE for intracardiac thrombus or aortic root dilation if murmur or embolic events
— Leukocytoclastic or lymphocytic vasculitis; supportive but not specific
— HLA-B51 in selected cases; MEFV gene testing if familial Mediterranean fever overlap suspected
Key distinction: BD ileocecal ulcers vs Crohn — BD has few, large, round/oval, deep ulcers without granulomas; Crohn has multiple, linear/serpiginous, transmural lesions with granulomas. Smoking status, perianal disease, and granulomas favor Crohn.
— Mild: isolated mucocutaneous and/or non-deforming arthritis
— Moderate: extensive skin, recurrent severe mucosal disease, anterior uveitis only
— Severe/sight- or life-threatening: posterior uveitis, retinal vasculitis, neuro-BD, major vessel involvement (aneurysm, large-vein thrombosis, Budd-Chiari), GI perforation/bleeding
— Young male sex
— Early age of onset
— Middle Eastern/East Asian ethnicity
— Major organ involvement at presentation
— Multidisciplinary care: rheumatology + ophthalmology ± neurology, vascular surgery, GI
— Tailor therapy to organ involvement and severity
— Recognize that disease activity decreases over time in most patients (10–20 years), but irreversible damage (vision loss, aneurysm) occurs early — aggressive early treatment is the principle
— Step 1: confirm diagnosis clinically (ICBD criteria, exclude mimics)
— Step 2: stage by organ involvement (ophtho, vascular, neuro, GI screens)
— Step 3: choose therapy by highest-severity organ affected
— Step 4: monitor response with symptom diary, ESR/CRP trend, organ-specific imaging
— Step 5: taper carefully; relapse is common
Step 3 management: A patient with only oral and genital ulcers does not need azathioprine on day 1 — start with colchicine + topical steroids. Reserve systemic immunosuppression for major organ disease or refractory mucocutaneous disease. Overtreating mild BD is a common board distractor.
Board pearl: Always screen for posterior uveitis at diagnosis even when the patient denies visual symptoms — silent retinal vasculitis upgrades therapy from colchicine to azathioprine ± anti-TNF.
— Topical: high-potency corticosteroids (triamcinolone in Orabase for oral, clobetasol for genital), topical sucralfate
— Systemic first-line: colchicine 0.5–1.5 mg/day — most evidence for genital ulcers, erythema nodosum, arthritis
— Refractory: apremilast (PDE4 inhibitor) — FDA-approved specifically for BD oral ulcers; significantly reduces ulcer count
— Severe/refractory: azathioprine, anti-TNF (adalimumab/infliximab), thalidomide (teratogenic, neuropathy risk)
— Colchicine first-line; NSAIDs PRN; intra-articular steroids for monoarticular flare; azathioprine or anti-TNF if persistent
— Systemic glucocorticoids + azathioprine OR cyclosporine as steroid-sparing first-line
— Severe/refractory or vision-threatening: infliximab or adalimumab preferred; interferon-α alternative
— Avoid cyclosporine in neuro-BD (neurotoxicity)
— Intravitreal steroid/anti-VEGF for macular edema as adjunct
— Immunosuppression is the primary therapy for thrombosis in BD (vessel wall inflammation drives clotting) — high-dose steroids + azathioprine, cyclophosphamide, or anti-TNF
— Anticoagulation is controversial; consider only after immunosuppression initiated and after excluding pulmonary artery aneurysm
— Pulmonary artery aneurysm: cyclophosphamide + high-dose steroids; embolization or surgery for life-threatening bleeding
— Pulse IV methylprednisolone → oral taper + azathioprine; escalate to infliximab or cyclophosphamide if severe
— Avoid cyclosporine (worsens neuro disease)
— 5-ASA, steroids, azathioprine; anti-TNF for refractory; surgery for perforation/bleeding
Board pearl: Cyclosporine + neuro-BD = wrong answer. Anti-TNF (infliximab/adalimumab) is the right answer for sight- or life-threatening refractory disease.
— First-line: high-dose IV methylprednisolone + monthly IV cyclophosphamide for 6–12 months
— Massive hemoptysis: bronchial/pulmonary artery embolization by interventional radiology — preferred over surgical resection due to multifocality
— Surgical resection reserved for refractory unilateral disease
— Never anticoagulate a PA aneurysm — bleeding risk outweighs thrombosis benefit
— Immunosuppression + elective repair when rupture risk high
— Endovascular repair preferred over open when feasible (lower pathergy risk at surgical site)
— Continue immunosuppression perioperatively to reduce anastomotic pseudoaneurysm
— Primary therapy: corticosteroids + azathioprine (or cyclophosphamide for severe)
— Anticoagulation: case-by-case; EULAR does not routinely recommend anticoagulation for BD DVT — clot is adherent and embolization to lung is rare; PA aneurysm must be excluded first
— CVST: anticoagulation is generally given plus immunosuppression
— Vitrectomy for non-clearing vitreous hemorrhage; cataract surgery during quiescent disease only (≥3 months inflammation-free)
— Intravitreal triamcinolone or dexamethasone implant for macular edema
— Indications: perforation, uncontrolled bleeding, obstruction, fistula
— High recurrence at anastomotic site (up to 50%) — perioperative immunosuppression and wider resection margins recommended
CCS pearl: For BD patient needing surgery — order rheumatology consult preoperatively, continue steroids with stress-dose coverage, avoid arterial lines when possible, and document the immunosuppression plan for postop care to prevent anastomotic complications.
— Uncommon (~3–5%); milder phenotype overall, fewer ocular and vascular complications
— Higher comorbidity burden complicates immunosuppression
— Maintain high suspicion when oral ulcers occur with new uveitis or unexplained DVT in older adults — but exclude malignancy-associated mimics first (paraneoplastic ulcers, MAGIC syndrome, MDS-associated VEXAS)
— Colchicine: reduce dose by 50% if CrCl 30–60; avoid combination with strong CYP3A4 inhibitors (clarithromycin) — fatal toxicity; avoid if CrCl <30 chronically
— Methotrexate: avoid if CrCl <30; reduce dose 30–60
— Azathioprine: check TPMT activity before initiating; reduce dose in renal impairment; monitor CBC closely
— Cyclosporine: nephrotoxic — avoid or use minimum dose with vigilant Cr/BP monitoring
— Cyclophosphamide: dose adjust; aggressive hydration and mesna to prevent hemorrhagic cystitis
— NSAIDs: avoid in CKD
— Azathioprine: dose-reduce; monitor LFTs (hepatotoxicity, NRH risk)
— Methotrexate: contraindicated in significant liver disease; baseline hep B/C screen, avoid alcohol
— Anti-TNF: screen and treat latent TB and hepatitis B reactivation risk before initiation
— Apremilast: no major hepatic adjustment but monitor mood (depression/suicidality)
— Inactivated influenza yearly, pneumococcal PCV20 or PCV15+PPSV23, recombinant zoster (≥18 with immunocompromise), HBV, HPV when eligible
— Live vaccines (MMR, varicella, yellow fever) contraindicated during high-dose immunosuppression — give ≥4 weeks before starting
Board pearl: Check TPMT or NUDT15 activity before azathioprine — homozygous deficiency causes life-threatening myelosuppression. This is a frequently tested pre-prescribing safety step.
— Disease activity often improves during pregnancy (especially mucocutaneous)
— Higher risk of thrombosis, preeclampsia, miscarriage, and preterm delivery — multidisciplinary care (rheum + MFM)
— Active major-organ disease at conception → worse outcomes; counsel to plan conception during remission ≥6 months
— Safe/acceptable: hydroxychloroquine, azathioprine (≤2 mg/kg/day), low-dose prednisone, sulfasalazine, colchicine (now considered compatible based on FMF data), TNF inhibitors (certolizumab preferred, minimal placental transfer; adalimumab/infliximab acceptable, hold live infant vaccines until 6 months)
— Contraindicated: methotrexate, mycophenolate, cyclophosphamide, thalidomide, apremilast (limited data)
— Wash-out periods: methotrexate 3 months, mycophenolate 6 weeks, leflunomide cholestyramine washout
— Estrogen-containing contraceptives carry thrombosis risk — prefer progestin-only or IUD in BD, especially with prior thrombosis or vascular involvement
— Compatible: hydroxychloroquine, prednisone, azathioprine, anti-TNF, colchicine
— Avoid: methotrexate, mycophenolate, cyclophosphamide
— Often presents with mucocutaneous and arthritis; family history more common
— PFAPA (periodic fever, aphthous stomatitis, pharyngitis, adenitis) is the major mimic in young children
— Pediatric criteria (PEDBD) require ≥3 of 6 features; rheumatology referral standard
— Anti-TNF increasingly first-line for severe pediatric disease
— Cyclophosphamide → premature ovarian failure; offer GnRH agonist (leuprolide) or oocyte/sperm cryopreservation before initiation, especially in young patients
Step 3 management: Young woman with BD asking about contraception → levonorgestrel IUD or DMPA, not combined oral contraceptive. This is a recurring outpatient counseling scenario.
— Blindness — leading cause of permanent morbidity; 25% lose useful vision without treatment, <5% with modern anti-TNF therapy
— Cataract, glaucoma (steroid-induced), macular edema, retinal detachment
— Pulmonary artery aneurysm rupture — leading cause of BD-related death (mortality 25–50% per episode)
— Aortic aneurysm rupture, dissection
— Budd-Chiari syndrome → liver failure (very poor prognosis)
— Cerebral venous sinus thrombosis → intracranial hypertension, infarct
— Recurrent DVT with post-thrombotic syndrome
— Anastomotic pseudoaneurysm at any vascular surgical site
— Progressive brainstem disease, cognitive decline, hemiparesis, seizures
— Higher relapse rate and worse prognosis in parenchymal vs non-parenchymal neuro-BD
— Perforation, massive hemorrhage, fistula, stricture
— High post-surgical recurrence at anastomosis
— Intracardiac thrombus (especially right ventricle), coronary aneurysm/vasculitis, endomyocardial fibrosis, pericardial tamponade
— Glomerulonephritis (rare), AA amyloidosis in chronic uncontrolled disease — proteinuria, nephrotic syndrome, progressive CKD
— Steroids: osteoporosis, diabetes, hypertension, cataracts, avascular necrosis, infection
— Cyclophosphamide: hemorrhagic cystitis, bladder cancer, infertility, MDS/AML
— Anti-TNF: TB and HBV reactivation, demyelination, paradoxical psoriasis
— Azathioprine: cytopenias, hepatotoxicity, increased non-melanoma skin cancer and lymphoma risk
— Thalidomide: peripheral neuropathy, teratogenicity, thrombosis
Board pearl: New-onset proteinuria in a long-standing BD patient — think AA amyloidosis, biopsy with Congo red stain (apple-green birefringence). Early IL-1 or anti-TNF therapy may slow progression.
— Massive hemoptysis (suspect PA aneurysm) — secure airway, type and cross, IR on standby
— Acute neuro-BD with brainstem signs, decreased consciousness, status epilepticus
— Aortic dissection or ruptured aneurysm
— GI perforation with peritonitis or massive bleeding
— Severe Budd-Chiari with hepatic failure
— New posterior uveitis or retinal vasculitis with vision change — same-day ophthalmology, often admit for IV steroid pulse
— New DVT, CVST, or major-vessel thrombosis
— Suspected GI BD with bleeding or obstruction
— Severe flare requiring IV cyclophosphamide initiation
— Rheumatology — diagnosis and immunosuppression plan
— Ophthalmology — every newly diagnosed patient, even without visual symptoms (slit-lamp + dilated exam)
— Neurology — any neuro symptom or unexplained headache
— Vascular surgery / IR — known or suspected aneurysm; embolization planning
— Gastroenterology — abdominal pain, bleeding, weight loss
— MFM — pregnant patients
— Dermatology — atypical lesions or pathergy interpretation
— Ophthalmology + retina specialist for uveitis follow-up
— New visual blurring, floaters, eye pain → ophtho today
— New focal neuro deficit, severe headache → ED/MRI
— Hemoptysis of any volume → CTA chest, do not anticoagulate
— Unilateral leg swelling → duplex US
— Abdominal pain with rebound → CT abdomen
CCS pearl: Sequence for a BD patient with new posterior uveitis: ophthalmology consult → IV methylprednisolone 1 g/day × 3 days → initiate azathioprine or anti-TNF → taper oral prednisone over weeks → outpatient retina follow-up at 2 weeks. Don't forget PJP prophylaxis (TMP-SMX) and PPI when chronic high-dose steroids start.
— Upper airway (saddle nose, sinusitis), lung nodules, RPGN
— c-ANCA / anti-PR3 positive; granulomatous vasculitis
— Lacks recurrent oral/genital aphthae and pathergy
— Pulmonary-renal syndrome, asthma+eosinophilia (EGPA)
— p-ANCA / anti-MPO positive
— Medium-vessel necrotizing vasculitis, microaneurysms on mesenteric angiogram
— Hepatitis B association; spares lungs
— No mucocutaneous aphthae
— Large-vessel vasculitis but without recurrent aphthae or uveitis pattern of BD
— MEFV mutation, recurrent serositis episodes, ethnic overlap with BD
— Treated with colchicine; can coexist with BD
— Lacks ocular/vascular signature
— HCV-associated, palpable purpura, neuropathy, glomerulonephritis
— Positive cryoglobulins, low C4
— Neutrophilic dermatoses; pathergy-like, but different lesion morphology
— Often paraneoplastic or IBD-associated
— Overlap of BD with relapsing polychondritis — auricular and nasal cartilage involvement
— Pediatric periodic fever with aphthae — episodic, predictable, fever-driven, resolves with steroids
Key distinction: Pathergy + posterior uveitis + recurrent genital ulcers is the BD signature triad and is not seen in ANCA-associated vasculitis. ANCA testing is negative in BD — a positive ANCA should redirect the workup.
— Most common BD mimic; isolated oral ulcers without other organ involvement
— Triggers: trauma, stress, nutritional deficiencies — check B12, folate, iron, zinc, vitamin D
— Oral aphthae, EN, uveitis, arthritis overlap with BD
— Granulomas, transmural inflammation, perianal disease favor Crohn
— Distinguishing can be very difficult — sometimes coexist
— Conjunctivitis (not uveitis), urethritis, oligoarthritis, oral ulcers, keratoderma blennorrhagicum
— HLA-B27 positive; post-infectious (GU or GI)
— Especially giant aphthous ulcers; always screen HIV in new severe oral/genital ulcers
— Recurrent painful genital/oral ulcers; vesicles before ulceration; PCR confirms
— Painless chancre (primary), mucous patches (secondary) — usually painless distinguishes
— Oral ulcers (usually painless, palatal), arthritis, photosensitivity
— ANA, dsDNA, low complement positive
— Acute, drug-triggered, target lesions, skin sloughing
— Recurrent ulcers every 21 days with neutrophil nadir — serial CBCs diagnostic
— Recurrent aphthae may be the only sign; check tTG-IgA
— Older patient with cytopenias and BD features — bone marrow biopsy
Step 3 management: First-line outpatient workup for "recurrent oral ulcers without other features" — CBC, B12, folate, iron studies, ferritin, tTG-IgA, HIV, HSV PCR if active lesion, ANA. Avoid jumping to BD or immunosuppression without exclusion.
— Mucocutaneous-only: colchicine ± apremilast indefinitely; topical steroids PRN flares
— Ocular: azathioprine or anti-TNF, often for years; taper after sustained quiescence ≥2 years
— Vascular: azathioprine maintenance after cyclophosphamide induction (3–6 months)
— Neuro-BD: azathioprine or infliximab maintenance × ≥3–5 years
— GI-BD: 5-ASA + azathioprine; anti-TNF if refractory
— Taper to lowest dose controlling disease; goal ≤7.5 mg prednisone/day
— Stress-dose coverage for surgery/illness when on ≥5 mg × ≥3 weeks
— Calcium 1000–1200 mg + vitamin D 800–1000 IU daily
— DEXA at baseline; bisphosphonate if T-score ≤−1.5 with chronic ≥5 mg prednisone, prior fragility fracture, or postmenopausal women
— TMP-SMX for PJP when on prednisone ≥20 mg × ≥4 weeks or combination immunosuppression
— Latent TB screen (IGRA) and HBV serologies before anti-TNF; treat LTBI prior
— Annual influenza, pneumococcal series, recombinant zoster, COVID-19 boosters
— BD increases atherosclerosis risk; treat hypertension, lipids, glucose aggressively
— Smoking cessation — smoking worsens BD vascular outcomes and mucocutaneous disease
— Continue immunosuppression; anticoagulation duration individualized
— Avoid estrogen contraceptives
— Lifelong ophthalmology follow-up; sunglasses, UV protection
— Screen for depression — chronic disease + apremilast risk
Board pearl: Before starting any anti-TNF: check IGRA, HBV surface antigen/core antibody, HCV, baseline CBC/LFT. Missing the TB screen is a classic safety-question wrong answer.
— Stable mucocutaneous: rheumatology every 3–6 months
— Active organ involvement: every 4–8 weeks until controlled
— Ophthalmology: every 1–3 months during active uveitis; every 6 months in remission
— Vascular imaging: CTA every 6–12 months for known aneurysms until stable
— Azathioprine: CBC and LFTs every 2 weeks × 1 month, then monthly × 3 months, then every 3 months
— Methotrexate: CBC, LFTs, Cr every 2–4 weeks initially, then every 8–12 weeks; folic acid 1 mg daily
— Cyclosporine: BP and Cr every 2 weeks initially, then monthly; trough levels; magnesium, uric acid, lipids
— Cyclophosphamide: CBC weekly during induction; UA for hematuria (bladder toxicity); aggressive hydration + mesna
— Anti-TNF: TB reassessment annually; CBC, LFTs every 3 months
— Colchicine: CBC, CK, Cr periodically
— Apremilast: weight, mood every visit; no routine labs required but monitor
— Patient ulcer diary, BDCAF (Behçet Disease Current Activity Form)
— ESR/CRP trends — supportive but not sufficient alone
— Annual fundus exam with fluorescein angiography in patients with prior ocular disease
— UA every 6 months screening for amyloid proteinuria in long-standing disease
— Avoid IM injections and unnecessary venipunctures (pathergy)
— Dental hygiene to reduce oral ulcer triggers; soft-bristle brush; avoid sodium lauryl sulfate toothpaste
— Sun protection; balanced diet
— Pregnancy planning during quiescence; contraception choice review
— Travel: maintain medications, alert to live vaccine restrictions, plan TB-endemic exposure
— Support resources: American Behçet's Disease Association
Step 3 management: A patient on azathioprine reports new sore throat and fever — stop azathioprine, check CBC immediately to evaluate for neutropenia. Don't reassure and reschedule.
— Document discussion of infection, malignancy, infertility, and teratogenicity risks before initiating cyclophosphamide, methotrexate, mycophenolate, thalidomide
— Thalidomide: REMS program enrollment required (prescriber, pharmacy, patient registration); pregnancy testing protocol mandatory
— Two forms of contraception required during methotrexate and mycophenolate
— Required before cyclophosphamide; offer GnRH agonist, oocyte/sperm cryopreservation
— Document patient's reproductive goals and decision
— Document that live vaccines (MMR, varicella, yellow fever, intranasal flu) are contraindicated during immunosuppression — failure to document is a safety lapse
— Inpatient discharge after BD flare: ensure rheumatology follow-up within 1–2 weeks, medication reconciliation including taper schedule, lab orders preplaced, and steroid stress-dose card issued
— Hand-off communication for active immunosuppression should be explicit; missed lab monitoring is a high-frequency adverse event
— TB infection detected during anti-TNF screening: report per state law and treat LTBI before biologic
— Failure to refer a BD patient with new visual symptoms within 24 hours and resulting vision loss is a recognized malpractice pattern — document referral, urgency, and patient education
— Document functional impact for ADA accommodation requests; visually impaired patients qualify for state services
— BD prevalence in immigrant populations from Silk Road countries — ensure interpreter use; written materials in patient's language improve adherence
— Many BD therapies (infliximab, anti-IL-1) are off-label — discuss evidence, cost, insurance coverage, and obtain documented assent
Board pearl: A patient on infliximab develops fever and cough. Pause biologic, evaluate for TB and opportunistic infection, do not restart until cleared. Continuing the biologic empirically is the wrong (and unsafe) answer.
Key distinction: Aphthae + uveitis + arthritis exists in many diseases — only pathergy, genital scarring, and posterior segment retinal vasculitis sharply favor BD.
— 28-year-old Turkish man with 4 oral ulcers/year for 3 years, two penile scars, recurrent leg "lumps." Sterile pustule appeared after IV placement. Next step? → Clinical diagnosis of BD; start colchicine; refer ophthalmology for screening
— Young BD patient with hemoptysis; intern starts heparin. Most appropriate next step? → Stop heparin, obtain CTA chest looking for pulmonary artery aneurysm
— Known BD patient with blurry vision, floaters. Slit-lamp shows vitritis, retinal vasculitis. Best therapy? → IV methylprednisolone pulse + azathioprine; escalate to infliximab if vision-threatening
— BD patient with new ataxia and brainstem MRI lesions. Which immunosuppressant should be avoided? → Cyclosporine
— 25-year-old with second DVT, negative thrombophilia, recurrent mouth ulcers. Diagnosis? → Behçet disease; treat with steroids + azathioprine; anticoagulation after PA aneurysm excluded
— BD patient with RLQ pain; colonoscopy shows 3 large punched-out oval ulcers in terminal ileum, no granulomas. Diagnosis vs Crohn? → GI-BD; treat 5-ASA + azathioprine
— Young woman with BD on methotrexate wants pregnancy. Next step? → Stop methotrexate ≥3 months prior; switch to azathioprine or certolizumab; folate supplementation
— BD patient with refractory uveitis planned for infliximab. Required tests before initiation? → IGRA, HBV serologies, HCV, CBC, LFT
— BD patient pre-azathioprine. Most important pharmacogenomic test? → TPMT or NUDT15 activity
— 15-year BD patient develops nephrotic-range proteinuria. Best test? → Kidney biopsy with Congo red staining for AA amyloidosis
Step 3 management: Stems frequently test what NOT to do: don't anticoagulate PA aneurysm, don't give cyclosporine in neuro-BD, don't give live vaccines on immunosuppression, don't start anti-TNF before TB screen.
Behçet disease is a clinically diagnosed variable-vessel vasculitis presenting with recurrent oral and genital aphthae, posterior uveitis, pathergy, vascular thrombosis or aneurysm, neurologic and GI involvement — treated by organ-tier severity with colchicine/apremilast for mucocutaneous disease and azathioprine, anti-TNF, or cyclophosphamide for sight- or life-threatening manifestations.
Board pearl: When you see a young Mediterranean or East Asian patient with recurrent ulcers, eye disease, and an unexpected aneurysm or thrombus — think Behçet, refer to ophthalmology the same day, start systemic immunosuppression early, and remember that the disease damages organs fastest in the first years — aggressive recognition and treatment preserve vision and life.